Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10121282 | 0.85 | ALDH1A1 (0.38) | DPP4KDM4ENPC1MAPTHTT | |
| SCHEMBL10154897 | 0.79 | DPP4 (0.51) | DPP4KDM4ENPC1MAPTRAB9A | |
| SCHEMBL12417817 | 0.79 | DPP4 (0.32) | DPP4KDM4ENPC1MAPTHTT | |
| SCHEMBL18067933 | 0.76 | DPP4 (0.38) | DPP4KDM4ENPC1MAPTL3MBTL1 | |
| SCHEMBL45854 | 0.73 | — | — | |
| SCHEMBL20270053 | 0.73 | ALDH1A1 (0.33) | KDM4ENPC1MAPTRAB9AALDH1A1 | |
| SCHEMBL18067911 | 0.73 | DPP4 (0.47) | DPP4KDM4ENPC1MAPTRAB9A | |
| SCHEMBL9769172 | 0.73 | ALDH1A1 (0.43) | KDM4ENPC1MAPTHTTRAB9A | |
| SCHEMBL10599245 | 0.72 | DPP4 (0.56) | DPP4KDM4EALDH1A1 | |
| SCHEMBL18067899 | 0.69 | ALDH1A1 (0.35) | KDM4ENPC1MAPTHTTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10752611-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2020-08-25 | — | — | US | disclosed |
| US-9765087-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2017-09-19 | — | — | US | disclosed |
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2012-03-29 | — | — | US | disclosed |
| US-8101643-B2 | Benzimidazole derivatives | ENANTA PHARMACEUTICALS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-10-14 | — | — | US | disclosed |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120076756-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | DPP4 327/4885KDM4E 553/4885NPC1 159/4885 |
| US-20100260715-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | DPP4 606/4885KDM4E 1193/4885NPC1 36/4885 |
| US-20100233122-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES | EIF2AK2, ZC3HAV1, HAVCR2 | DPP4 327/4885KDM4E 553/4885NPC1 159/4885 |
| US-10752611-B2 | Benzimidazole derivatives | EIF2AK2, ZC3HAV1, ZC3HAV1L | DPP4 362/4885KDM4E 437/4885NPC1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.